HEALTH STATE UTILITIES IN PATIENTS WITH RELAPSING REMITTING MULTIPLE SCLEROSIS TREATED WITH CLADRIBINE TABLETS

被引：0
|
作者：
Wong, S. L. [1 ]
Hohnhorst, P., V [1 ]
Hettle, R. [2 ]
Konings, P. [3 ]
机构：
[1] EMD Serono Inc, Billerica, MA USA
[2] PAREXEL Int, London, England
[3] PAREXEL Int, Stockholm, Sweden
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 09期
关键词：
D O I：
10.1016/j.jval.2017.08.1961
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PND47
引用
收藏
页码：A725 / A725
页数：1
相关论文
共 50 条
  • [1] Cladribine Tablets In Relapsing-Remitting Multiple Sclerosis
    Muir, Victoria J.
    Plosker, Greg L.
    CNS DRUGS, 2011, 25 (03) : 239 - 249
  • [2] Prevalence of disability improvement in relapsing-remitting multiple sclerosis patients treated with cladribine tablets
    Signori, Alessio
    Ponzano, Marta
    Alexandri, Nektaria
    Giovannoni, Gavin
    Sormani, Maria Pia
    EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 (07) : 2144 - 2147
  • [3] Cladribine tablets for the treatment of relapsing-remitting multiple sclerosis
    Comi, Giancarlo
    Hartung, Hans-Peter
    Kurukulasuriya, Nuwan C.
    Greenberg, Steven J.
    Scaramozza, Matthew
    EXPERT OPINION ON PHARMACOTHERAPY, 2013, 14 (01) : 123 - 136
  • [4] Correction to: Cladribine Tablets: In Relapsing-Remitting Multiple Sclerosis
    Victoria J. Muir
    Greg L. Plosker
    CNS Drugs, 2020, 34 : 447 - 447
  • [5] Cladribine Tablets for Relapsing–Remitting Multiple Sclerosis: A Clinician’s Review
    Gavin Giovannoni
    Joela Mathews
    Neurology and Therapy, 2022, 11 : 571 - 595
  • [6] CLARITY: An Analysis of Severity and Frequency of Relapses in Patients with Relapsing-remitting Multiple Sclerosis Treated with Cladribine Tablets or Placebo
    Schippling, S.
    Sormani, M. P.
    De Stefano, N.
    Giovannoni, G.
    King, J.
    Galazka, A.
    Keller, B.
    Alexandri, N.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 (03) : 466 - 467
  • [7] Cladribine Tablets for Relapsing-Remitting Multiple Sclerosis: A Clinician's Review
    Giovannoni, Gavin
    Mathews, Joela
    NEUROLOGY AND THERAPY, 2022, 11 (02) : 571 - 595
  • [8] CLARITY: an analysis of severity and frequency of relapses in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets or placebo
    Schippling, S.
    Sormani, M. P.
    De Stefano, N.
    Giovannoni, G.
    Galazka, A.
    Keller, B.
    Alexandri, N.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 258 - 259
  • [9] Reduced grey matter atrophy in patients with relapsing multiple sclerosis treated with cladribine tablets
    Battaglini, M.
    Sormani, M. P.
    Luchetti, L.
    Gentile, G.
    Cortese, R.
    Alexandri, N.
    De Stefano, N.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 231 - 231
  • [10] BUDGET IMPACT ANALYSIS OF CLADRIBINE TABLETS FOR TREATMENT OF PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS IN BULGARIA
    Djambazov, S.
    Slavchev, G.
    Dineva, T.
    Panayotov, P.
    Vekov, T.
    VALUE IN HEALTH, 2018, 21 : S205 - S205
12345